Tags

Type your tag names separated by a space and hit enter

How to protect doxorubicin-induced cardiomyopathy in male albino rats?
J Cardiovasc Pharmacol 2010; 55(3):262-8JC

Abstract

The present study was designed to compare the cardioprotective effects of the combination of lisinopril with growth hormone over lisinopril alone in doxorubicin (Dox)-induced cardiomyopathy in rats. Forty male Wister albino rats were divided into 4 groups: group 1, control group; group 2, received Dox; group 3, received lisinopril + Dox; and group 4, received lisinopril + Dox + growth hormone. Dox (cumulative dose) was administered to rats in 6 equal intraperitoneal injections over a period of 2 weeks. Histopathological changes and plasma aspartate aminotransferase, lactate dehydrogenase, and creatine kinase and plasma levels of matrix metalloproteinase (MMP)-2, tissue inhibitor matrix metalloproteinase (TIMP)-1, and cardiac inducible nitric oxide synthase (iNOS) messenger RNA (mRNA) expression were determined 9 weeks after the first dose of Dox. Dox produced cardiac structural injury and significant elevation in plasma levels of cardiac enzymes, MMP-2, and cardiac iNOS mRNA expression together with significant reduction in plasma TIMP-1 level. Lisinopril significantly decreases plasma MMP-2 level and cardiac iNOS mRNA expression by 13% and 15%, respectively, in group 3 compared with 36% and 47%, respectively, in group 4 as compared with group 2. In addition, compared with Dox group, lisinopril significantly increases plasma TIMP-1 level by 23% compared with 49% in group 4. We can conclude that the combination of lisinopril and growth hormone produced better cardioprotective effect against Dox-induced cardiomyopathy. This effect may be attributed on their antiremodeling actions by regulating plasma MMP-2/TIMP-1 levels and to the reduction of cardiac iNOS mRNA expression.

Authors+Show Affiliations

Department of Medical Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt. olfatshaker@yahoo.comNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

20051877

Citation

Shaker, Olfat, and Doaa A. Sourour. "How to Protect Doxorubicin-induced Cardiomyopathy in Male Albino Rats?" Journal of Cardiovascular Pharmacology, vol. 55, no. 3, 2010, pp. 262-8.
Shaker O, Sourour DA. How to protect doxorubicin-induced cardiomyopathy in male albino rats? J Cardiovasc Pharmacol. 2010;55(3):262-8.
Shaker, O., & Sourour, D. A. (2010). How to protect doxorubicin-induced cardiomyopathy in male albino rats? Journal of Cardiovascular Pharmacology, 55(3), pp. 262-8. doi:10.1097/FJC.0b013e3181cf91ac.
Shaker O, Sourour DA. How to Protect Doxorubicin-induced Cardiomyopathy in Male Albino Rats. J Cardiovasc Pharmacol. 2010;55(3):262-8. PubMed PMID: 20051877.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - How to protect doxorubicin-induced cardiomyopathy in male albino rats? AU - Shaker,Olfat, AU - Sourour,Doaa A, PY - 2010/1/7/entrez PY - 2010/1/7/pubmed PY - 2010/7/3/medline SP - 262 EP - 8 JF - Journal of cardiovascular pharmacology JO - J. Cardiovasc. Pharmacol. VL - 55 IS - 3 N2 - The present study was designed to compare the cardioprotective effects of the combination of lisinopril with growth hormone over lisinopril alone in doxorubicin (Dox)-induced cardiomyopathy in rats. Forty male Wister albino rats were divided into 4 groups: group 1, control group; group 2, received Dox; group 3, received lisinopril + Dox; and group 4, received lisinopril + Dox + growth hormone. Dox (cumulative dose) was administered to rats in 6 equal intraperitoneal injections over a period of 2 weeks. Histopathological changes and plasma aspartate aminotransferase, lactate dehydrogenase, and creatine kinase and plasma levels of matrix metalloproteinase (MMP)-2, tissue inhibitor matrix metalloproteinase (TIMP)-1, and cardiac inducible nitric oxide synthase (iNOS) messenger RNA (mRNA) expression were determined 9 weeks after the first dose of Dox. Dox produced cardiac structural injury and significant elevation in plasma levels of cardiac enzymes, MMP-2, and cardiac iNOS mRNA expression together with significant reduction in plasma TIMP-1 level. Lisinopril significantly decreases plasma MMP-2 level and cardiac iNOS mRNA expression by 13% and 15%, respectively, in group 3 compared with 36% and 47%, respectively, in group 4 as compared with group 2. In addition, compared with Dox group, lisinopril significantly increases plasma TIMP-1 level by 23% compared with 49% in group 4. We can conclude that the combination of lisinopril and growth hormone produced better cardioprotective effect against Dox-induced cardiomyopathy. This effect may be attributed on their antiremodeling actions by regulating plasma MMP-2/TIMP-1 levels and to the reduction of cardiac iNOS mRNA expression. SN - 1533-4023 UR - https://www.unboundmedicine.com/medline/citation/20051877/How_to_protect_doxorubicin_induced_cardiomyopathy_in_male_albino_rats L2 - http://Insights.ovid.com/pubmed?pmid=20051877 DB - PRIME DP - Unbound Medicine ER -